BILTHOVEN, The Netherlands, November 6 /PRNewswire/ -- InteRNA Technologies B.V. is pleased to announce that it has joined the SIROCCO research consortium consisting of 25 world-class laboratories and companies from 10 countries for studying how RNA silencing could be used to treat life-threatening diseases, including cancer.
SIROCCO stands for "Silencing RNAs: organisers and coordinators of complexity in eukaryotic organisms". InteRNA will join for the remaining 2.5 years of this EUR 11.8 million funded four-year Integrated Project under the EU Sixth Framework Programme.
InteRNA's contribution will focus on discovery, data mining and development of diagnostic miRNA and other small RNA profiles through next-generation sequencing, in combination with InteRNA's proprietary small RNA bioinformatics pipeline, miR-Intess(TM), of diverse patient sample sets provided by consortium members and other sources.
"Pleased as we were by the invitation to become a partner in the SIROCCO consortium, we are very excited that we now can participate in this unique small RNA consortium as it will further support the progression of our discovery and development programs," said Roel Schaapveld, Chief Operating Officer of InteRNA Technologies.
About InteRNA Technologies B.V.
InteRNA Technologies B.V. actively explores and exploits opportunities to translate its unique collection of miRNAs and miRNA discovery and validation technologies into successful diagnostic, prognostic and therapeutic applications. The company's primary focus is to unravel the role of its proprietary miRNAs in cancer.
InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and has established close relationships with the leading miRNA research groups of its founders Edwin Cuppen, PhD, and Eugene Berezikov, PhD.
See for more information http://www.interna-technologies.com.
For further information on the SIROCCO project, please visit http://www.sirocco-project.eu.
CONTACT: Contact: Roel Q.J. Schaapveld, PhD, MBA, COO, InteRNA
Technologies B.V., Phone: +31-30-229-6095, E-mail: